FindTrial
Sign In

Study of a novel serum marker IIRPCs for monitoring myeloma replase

Study of a novel serum marker IIRPCs for monitoring the progression of myeloma

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2200058235
Enrollment
Unknown
Registered
2022-04-03
Start date
2022-04-11
Completion date
Unknown
Last updated
2023-12-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple Myeloma

Interventions

Observation group:

Sponsors

Beijing Chaoyang Hospital, Capital Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Newly diagnosed/relapsed MM patients who need treatment.

Exclusion criteria

Exclusion criteria: Other plasma cell disease patients

Design outcomes

Primary

MeasureTime frame
serum immunoinflammation-related protein complexes (IIRPCs);glycopeptide;lipid molecules;—

Countries

China

Contacts

Public ContactLiu Aijun

Beijing Chaoyang Hospital, Capital Medical University

aijun.liu72@yahoo.com+86 13521030376

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026